|
1
|
March WA, Moore VM, Willson KJ, Phillips
DI, Norman RJ and Davies MJ: The prevalence of polycystic ovary
syndrome in a community sample assessed under contrasting
diagnostic criteria. Hum Reprod. 25:544–551. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Teede HJ, Misso ML, Deeks AA, Moran LJ,
Stuckey BG, Wong JL, Norman RJ and Costello MF; Guideline
Development Groups, : Assessment and management of polycystic ovary
syndrome: Summary of an evidence-based guideline. Med J Aust.
195:S65–S112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moran LJ, Misso ML, Wild RA and Norman RJ:
Impaired glucose tolerance, type 2 diabetes and metabolic syndrome
in polycystic ovary syndrome: A systematic review and
meta-analysis. Hum Reprod Update. 16:347–363. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Qin KN and Rosenfield RL: Role of
cytochrome P450c17 in polycystic ovary syndrome. Mol Cell
Endocrinol. 145:111–121. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Garvey WT, Maianu L, Hancock JA,
Golichowski AM and Baron A: Gene-expression of GLUT4 in
skeletal-muscle from insulin-resistant patients with obesity, IGT,
GDM, and NIDDM. Diabetes. 41:465–475. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shepherd PR and Kahn BB: Glucose
transporters and insulin action-implications for insulin resistance
and diabetes mellitus. N Engl J Med. 341:248–257. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mioni R, Chiarelli S, Xamin N, Zuliani L,
Granzotto M, Mozzanega B, Maffei P, Martini C, Blandamura S, Sicolo
N and Vettor R: Evidence for the presence of glucose transporter 4
in the endometrium and its regulation in polycystic ovary syndrome
patients. J Clin Endocrinol Metab. 89:4089–4096. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Frolova AI and Moley KH: Glucose
transporters in the uterus: An analysis of tissue distribution and
proposed physiological roles. Reproduction. 142:211–220. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Trayhurn P and Beattie JH: Physiological
role of adipose tissue: White adipose tissue as an endocrine and
secretory organ. Proc Nutr Soc. 60:329–339. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sainz N, Gonzalez-Navarro CJ, Martinez JA
and Moreno-Aliaga MJ: Leptin signaling as a therapeutic target of
obesity. Expert Opin Ther Targets. 19:893–909. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pusalkar M, Meherji P, Gokral J,
Savardekar L, Chinnaraj S and Maitra A: Obesity and polycystic
ovary syndrome: Association with androgens, leptin and its
genotypes. Gynecol Endocrinol. 26:874–882. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lian Y, Zhao F and Wang W: Central leptin
resistance and hypothalamic inflammation are involved in
letrozole-induced polycystic ovary syndrome rats. Biochem Biophys
Res Commun. 476:306–312. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Prelevic GM, Puzigaca Z and Balint-Peric
LA: Effects of an oral contraceptive containing cyproterone acetate
(Diane-35) on the symptoms, hormone profile, and ovarian volume of
hirsute women with polycystic ovarian syndrome. Ann N Y Acad Sci.
687:255–262. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Palomba S, Falbo A, Russo T, Orio F,
Tolino A and Zullo F: Systemic and local effects of metformin
administration in patients with polycystic ovary syndrome (PCOS):
Relationship to the ovulatory response. Hum Reprod. 25:1005–1013.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Spritzer PM, Motta AB, Sir-Petermann T and
Diamanti-Kandarakis E: Novel strategies in the management of
polycystic ovary syndrome. Minerva Endocrinol. 40:195–212.
2015.PubMed/NCBI
|
|
16
|
Raja-Khan N, Stener-Victorin E, Wu X and
Legro RS: The physiological basis of complementary and alternative
medicines for polycystic ovary syndrome. Am J Physiol Endocrinol
Metab. 301:E1–E10. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhou J and Qu F: Treating gynaecological
disorders with traditional Chinese medicine: A review. Afr J Tradit
Complement Altern Med. 6:494–517. 2009.PubMed/NCBI
|
|
18
|
Zhou LR and Yu J: Clinical observation on
treatment of hyperinsulinemia and hyperandrogenism anovulatory
patient with replenishing kidney-yin drugs. Zhongguo Zhong Xi Yi
Jie He Za Zhi. 16:515–518. 1996.(In Chinese). PubMed/NCBI
|
|
19
|
Hou J, Yu J and Wei M: Study on treatment
of hyperandrogenism and hyperinsulinism in polycystic ovary
syndrome with Chinese herbal formula ‘tiangui fang’. Zhongguo Zhong
Xi Yi Jie He Za Zhi. 20:589–592. 2000.(In Chinese). PubMed/NCBI
|
|
20
|
Sun F and Yu J: Effect of tiangui recipe
on serum leptin and pituitary gonadotropin in androgen-sterilized
rats. Zhongguo Zhong Xi Yi Jie He Za Zhi. 19:350–352. 1999.(In
Chinese). PubMed/NCBI
|
|
21
|
Yu J and Cheng HY: Experimental studies on
the relation of the kidney and reproduction. Zhong Xi Yi Jie He Za
Zhi. 9548–551. (517)1989.(In Chinese). PubMed/NCBI
|
|
22
|
Kuek S, Wang WJ and Gui SQ: Efficacy of
Chinese patent medicine Tian Gui Capsule in patients with
polycystic ovary syndrome: A randomized controlled trial. Zhong Xi
Yi Jie He Xue Bao. 9:965–972. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang XJ, Chen YQ, Gui SQ, Qian QH and Guo
SX: Clinical observation on Tiangui Capsule for 110 cases of
polycystic ovary syndrome. J Trad Chin Med. 55:1835–1840. 2014.(In
Chinese).
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fan YS, Sasi R, Lee C, Winter JS, Waterman
MR and Lin CC: Localization of the human CYP17 gene (cytochrome
P450(17alpha) to 10q24.3 by fluorescence in situ hybridization and
simultaneous chromosome banding. Genomics. 14:1110–1111. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
McNatty KP, Makris A, DeGrazia C,
Osathanondh R and Ryan KJ: The production of progesterone,
androgens, and estrogens by granulosa cells, thecal tissue, and
stromal tissue from human ovaries in vitro. J Clin Endocrinol
Metab. 49:687–699. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Moon YS, Tsang BK, Simpson C and Armstrong
DT: 17beta-Estradiol biosynthesis in cultured granulosa and thecal
cells of human ovarian follicles: Stimulation by
follicle-stimulating hormone. J Clin Endocrinol Metab. 47:263–267.
1978. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Harlow CR, Bradshaw AC, Rae MT, Shearer KD
and Hillier SG: Oestrogen formation and connective tissue growth
factor expression in rat granulosa cells. J Endocrinol. 192:41–52.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schulte MM, Tsai JH and Moley KH: Obesity
and PCOS: The effect of metabolic derangements on endometrial
receptivity at the time of implantation. Reprod Sci. 22:6–14. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cai D, Yuan M, Frantz DF, Melendez PA,
Hansen L, Lee J and Shoelson SE: Local and systemic insulin
resistance resulting from hepatic activation of IKK-beta and
NF-kappaB. Nat Med. 11:183–190. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cai D, Frantz JD, Tawa NE Jr, Melendez PA,
Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ and
Shoelson SE: IKKbeta/NF-kappaB activation causes severe muscle
wasting in mice. Cell. 119:285–298. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yuan M, Konstantopoulos N, Lee J, Hansen
L, Li ZW, Karin M and Shoelson SE: Reversal of obesity- and
diet-induced insulin resistance with salicylates or targeted
disruption of IKKbeta. Science. 293:1673–1677. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang X, Zhang G, Zhang H, Karin M, Bai H
and Cai D: Hypothalamic IKKbeta/NF-kappaB and er stress link
overnutrition to energy imbalance and obesity. Cell. 135:61–73.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Benzler J, Ganjam GK, Pretz D, Oelkrug R,
Koch CE, Legler K, Stöhr S, Culmsee C, Williams LM and Tups A:
Central inhibition of IKKβ/NF-κB signaling attenuates high-fat
diet-induced obesity and glucose intolerance. Diabetes.
64:2015–2027. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mori H, Hanada R, Hanada T, Aki D, Mashima
R, Nishinakamura H, Torisu T, Chien KR, Yasukawa H and Yoshimura A:
Socs3 deficiency in the brain elevates leptin sensitivity and
confers resistance to diet-induced obesity. Nat Med. 10:739–743.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Howard JK, Cave BJ, Oksanen LJ, Tzameli I,
Bjorbaek C and Flier JS: Enhanced leptin sensitivity and
attenuation of diet-induced obesity in mice with haploinsufficiency
of Socs3. Nat Med. 10:734–738. 2004. View
Article : Google Scholar : PubMed/NCBI
|
